Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05100862 · ClinicalTrials.gov registry record · Phase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

A Phase 3 study of Marginal Zone Lymphoma and Relapsed/Refractory Follicular Lymphoma, sponsored by BeiGene.

Recruiting
Registry status
Phase 3
Development phase
780
Enrollment target
20
Study locations

NCT05100862: Recruiting Phase 3 study of Marginal Zone Lymphoma and Relapsed/Refractory Follicular Lymphoma, sponsored by BeiGene.

NCT05100862 is a Phase 3 study of Marginal Zone Lymphoma and Relapsed/Refractory Follicular Lymphoma that is actively recruiting participants, run by BeiGene. The registered enrollment target is 780 participants, above the 87-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (797% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05100862, a Phase 3 study of Marginal Zone Lymphoma and Relapsed/Refractory Follicular Lymphoma, is actively recruiting participants, sponsored by BeiGene.

RECRUITING
Registry status
Phase 3
Development phase
780 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Conditions Studied

Marginal Zone Lymphoma Relapsed/Refractory Follicular Lymphoma

Interventions

  • DRUG Zanubrutinib
  • DRUG Obinutuzumab
  • DRUG Rituximab
  • DRUG Lenalidomide

Study Locations (20)

California

  • Ucsf Fresno University of California San Francisco Fresno - Fresno
  • Kaiser Permanente Southern California - Irvine
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • Los Angeles Cancer Network - Los Angeles
  • Valkyrie Clinical Trials - Los Angeles
  • UCLA Hematologyoncology - Los Angeles
  • Scripps Health - San Diego
  • Sharp Healthcare Sharp Memorial Hospital - San Diego

Florida

  • Baptist Md Anderson Cancer Center - Jacksonville
  • Ascension Sacred Heart - Pensacola

Kansas

  • Cotton Oneil Cancer Center - Topeka
  • Cancer Center of Kansas - Wichita

Maryland

  • Luminis Health Anne Arundel Medical Center - Annapolis
  • University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore

Georgia

  • Northwest Georgia Oncology Centers Marietta - Marietta

Illinois

  • Cancer Care Specialists of Illinois - Decatur

Indiana

  • Fort Wayne Medical Oncology and Hematology - Fort Wayne

Iowa

  • Mission Cancer and Blood - Waukee

Trial Details

FieldValue
Enrollment Target 780 participants
Start Date 2022-03-10
Est. Completion 2030-06
Phase Phase 3
BeiGene

65 total trials

What NCT05100862 shows while recruiting

NCT05100862 is an interventional study that assigns participants to a tested intervention. The registered 780 participants enrollment target is mid-sized for trials with a published cap, above the 87-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (797% higher).

The record links to 2 conditions, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.

NCT05100862 names 20 study sites across 10 states, led by California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT05100862 about?

NCT05100862 is a clinical study titled "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma". The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accord...

What is the current status of trial NCT05100862?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 780 participants. The study started on 2022-03-10. Estimated completion is 2030-06.

What conditions does trial NCT05100862 study?

This clinical trial studies the following conditions: Marginal Zone Lymphoma, Relapsed/Refractory Follicular Lymphoma.

What interventions are being tested in trial NCT05100862?

The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Rituximab (DRUG), Lenalidomide (DRUG).

Who is sponsoring clinical trial NCT05100862?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05100862 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Marginal Zone Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05100862's enrollment target sits among peer trials

780 1st of 49 higher than 49 of 49 other Marginal Zone Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Marginal Zone Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05046613 · 780 participants

    Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

  • NCT05513872 · 780 participants · Phase 1

    Overcoming Nicotine Dependence to Enable Quitting

  • NCT06310031 · 780 participants · NA

    Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

  • NCT06312137 · 780 participants · Phase 3

    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05100862

Source: ClinicalTrials.gov NCT05100862, the US trial registry maintained by the National Library of Medicine. NCT05100862 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.